Homology Medicines (FIXX) P/E Ratio
P/E Ratio as of Jul 25, 2025: -0.45
Average-0.4014
Median-0.4200
Minimum-0.6700
Maximum-0.2800
-0.45
Past Month-0.13 (40.62%)
The P/E ratio for Homology Medicines (FIXX) is -0.45 as of Jul 25, 2025. This represents a decrease of -49.44% compared to its 12-month average P/E ratio of -0.89. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Homology Medicines P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Homology Medicines’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Homology Medicines to industry peers.
Homology Medicines P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Homology Medicines’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Homology Medicines to industry peers.
Homology Medicines (FIXX) P/E Ratio Insights
See Homology Medicines’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Homology Medicines (FIXX)
Order type
Buy in
Order amount
Est. shares
0 shares
Homology Medicines (FIXX) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jul 1, 2025 | $1.44 | -0.29 |
| Jun 2, 2025 | $1.83 | -0.37 |
| May 1, 2025 | $1.56 | -0.15 |
| Apr 1, 2025 | $1.50 | -0.14 |
| Mar 3, 2025 | $2.16 | -0.15 |
| Feb 3, 2025 | $3.02 | -0.21 |
| Jan 2, 2025 | $3.45 | -0.24 |
Homology Medicines (FIXX) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -0.45 | +87.50% |
| 2024 | -0.24 | -11.11% |
| 2023 | -0.27 | -98.07% |
| 2022 | -13.97 | +546.76% |
| 2021 | -2.16 | -46.27% |
| 2020 | -4.02 | — |
FAQs About Homology Medicines (FIXX) P/E ratio
The latest P/E ratio of Homology Medicines (FIXX) is -0.45, as of Jul 25, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Homology Medicines’s last 12-month average P/E ratio is -0.89, compared to its current P/E ratio of -0.45. This reflects a decrease of -49.44%.
Homology Medicines’s current P/E ratio of -0.45 is lower than its last 12-month average P/E of -0.89. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Homology Medicines’s average P/E ratio over the last 3 years is -6.28. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Homology Medicines’s average P/E ratio over the last 5 years is -7.19. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.